Clinical Trials Logo

Adrenal Gland Pheochromocytoma clinical trials

View clinical trials related to Adrenal Gland Pheochromocytoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05142241 Recruiting - Clinical trials for Malignant Solid Neoplasm

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Start date: July 11, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether combination of talazoparib and temozolomide works to shrink tumors in patients with rare cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Talazoparib is an inhibitor of poly adenosine diphosphate-ribose polymerase (PARP), an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Temozolomide is in a class of medications called alkylating agents. It damages the cell's DNA and may kill cancer cells. Giving talazoparib in combination with temozolomide may help shrink advanced rare cancers or stop them from growing.